Eleven relevant presentations are scheduled, covering all five ImprimisRx portfolios
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest U.S. meeting of anterior segment surgeons, which integrates a scientific program dedicated to the needs of surgeons, specialists, practice management staff, and ophthalmic technicians and nurses.
At the conference, attendees will have the opportunity to meet with ImprimisRx representatives at Exhibit #1427 to learn more about new ImprimisRx proprietary formulations launching this year, including:
- Klarity-A™ Drops (preservative-free ophthalmic solution + azithromycin 1%)
- Klarity-B™ Drops (preservative-free ophthalmic solution + betamethasone 0.1%)
- Klarity-L™ Drops (preservative-free ophthalmic solution + loteprednol 0.5%)
- LessDrops® formulations with moxifloxacin
- Povidone Iodine 5%
There will be a combination of eleven relevant physician presentations or posters, which will touch on all five ImprimisRx portfolios: Dropless®, LessDrops, Simple Drops®, Total Tears®, and IV Free®. Additionally, ImprimisRx is hosting an open house at the Hard Rock Hotel in downtown San Diego from 5:30-7:30pm on Saturday May 4th, where anyone registered can learn more about the robust portfolio of ophthalmic compound medications offered by ImprimisRx. Please register by clicking here if you have an interest in attending the open house.
John Saharek, President of ImprimisRx, commented, “We are excited to have our largest presence ever at ASCRS, where paper presentations, posters, speakers, and an instructional course will detail the value proposition of our unique portfolio. ImprimisRx is also announcing the launch of a number of new ophthalmology-focused innovative compounded formulations, some of which represent completely new markets for us. Our team is excited to update the ophthalmic community on our unique offerings which we believe address unmet needs. We look forward to visiting with customers and shareholders alike at Exhibit #1427.”
ImprimisRx is the nation’s leading ophthalmology compounding business, serving thousands of ophthalmologists and optometrists in all 50 states, with more than 20 proprietary ophthalmic formulations. ImprimisRx is headquartered in San Diego, CA and owns two FDA-inspected production and dispensing facilities in Ledgewood, New Jersey. There have been over one million eyes served by the formulations produced at these facilities.
About Harrow Health
Harrow Health, Inc. (HROW) owns a portfolio of healthcare businesses, including the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
No ImprimisRx compounded formulation is FDA-approved. All ImprimisRx formulations are customizable. Other than drugs compounded at a registered outsourcing facility, all ImprimisRx compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.
All educational content of the ASCRS•ASOA Annual Meeting is planned by its program committee, and ASCRS•ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.
Holliday Communications, Inc.
Source: Harrow Health, Inc.